Alto Neuroscience (NYSE:ANRO) Stock Price Up 1.6% – Here’s What Happened

Alto Neuroscience, Inc. (NYSE:ANRO) shares traded up 1.6% on Tuesday . The company traded as high as $14.70 and last traded at $14.52. 1,624,103 shares were traded during mid-day trading, an increase of 559% from the average session volume of 246,314 shares. The stock had previously closed at $14.29.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on ANRO shares. William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a research note on Tuesday, September 10th. Wedbush reiterated an “outperform” rating and issued a $29.00 price objective on shares of Alto Neuroscience in a research report on Tuesday, September 10th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $33.80.

Alto Neuroscience Stock Up 1.6 %

The firm has a fifty day moving average of $12.33 and a 200-day moving average of $12.54. The company has a current ratio of 19.85, a quick ratio of 19.85 and a debt-to-equity ratio of 0.04.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings data on Tuesday, August 13th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.07. As a group, research analysts predict that Alto Neuroscience, Inc. will post -2.63 earnings per share for the current year.

Institutional Investors Weigh In On Alto Neuroscience

Several institutional investors and hedge funds have recently made changes to their positions in the business. Federated Hermes Inc. boosted its position in shares of Alto Neuroscience by 33.3% in the 2nd quarter. Federated Hermes Inc. now owns 12,000 shares of the company’s stock worth $128,000 after buying an additional 3,000 shares in the last quarter. Rhumbline Advisers purchased a new stake in shares of Alto Neuroscience in the 2nd quarter worth about $113,000. University of Texas Texas AM Investment Managment Co. acquired a new position in Alto Neuroscience in the 1st quarter valued at about $340,000. Bank of New York Mellon Corp acquired a new position in Alto Neuroscience in the 2nd quarter valued at about $252,000. Finally, Bowie Capital Management LLC acquired a new position in Alto Neuroscience in the 2nd quarter valued at about $462,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.